<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Medical and Social Expert Evaluation and Rehabilitation</journal-id><journal-title-group><journal-title xml:lang="en">Medical and Social Expert Evaluation and Rehabilitation</journal-title><trans-title-group xml:lang="ru"><trans-title>Медико-социальная экспертиза и реабилитация</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1560-9537</issn><issn publication-format="electronic">2412-2092</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">36003</article-id><article-id pub-id-type="doi">10.18821/1560-9537-2018-21-3-160-165</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">ORGANIZATION OF DRUG REIMBURSEMENT IN DIFFERENT REGIONS OF THE WORLD</article-title><trans-title-group xml:lang="ru"><trans-title>ОСОБЕННОСТИ ОРГАНИЗАЦИИ ЛЕКАРСТВЕННОГО ОБЕСПЕЧЕНИЯ В РАЗЛИЧНЫХ РЕГИОНАХ МИРА</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Puzin</surname><given-names>S. N</given-names></name><name xml:lang="ru"><surname>Пузин</surname><given-names>С. Н</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Grechko</surname><given-names>A. V</given-names></name><name xml:lang="ru"><surname>Гречко</surname><given-names>А. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Prianikov</surname><given-names>I. V</given-names></name><name xml:lang="ru"><surname>Пряников</surname><given-names>И. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Malichenko</surname><given-names>Vladislav S.</given-names></name><name xml:lang="ru"><surname>Маличенко</surname><given-names>Владислав Сергеевич</given-names></name></name-alternatives><bio xml:lang="en"><p>MD, PhD, Researcher FSBI “Federal Scientific and Clinical Center for Reanimation and Rehabilitation», 141534, Moscow, Russian Federation</p></bio><bio xml:lang="ru"><p>кандидат юридических наук, научный сотрудник ФГБНУ «Федеральный научно-клинический центр реаниматологии и реабилитологии», 141534, г. Москва</p></bio><email>vlad.malichenko@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Chludeeva</surname><given-names>T. A</given-names></name><name xml:lang="ru"><surname>Хлудеева</surname><given-names>Т. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Puzin</surname><given-names>S. S</given-names></name><name xml:lang="ru"><surname>Пузин</surname><given-names>С. С</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Russian Medical Academy of Continuous Professional Education</institution></aff><aff><institution xml:lang="ru">ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет)</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Федеральный научно-клинический центр реаниматологии и реабилитологии»</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Department of medical and health work and insurance of the Administrative Department of the Central Bank of the Russian Federation( Bank of Russia)</institution></aff><aff><institution xml:lang="ru">Управление медицинско-оздоровительной работы и страхования Административного департамента Центрального банка Российской Федерации (Банк России)</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2018</year></pub-date><volume>21</volume><issue>3-4</issue><issue-title xml:lang="en">VOL 21, NO3-4 (2018)</issue-title><issue-title xml:lang="ru">ТОМ 21, №3-4 (2018)</issue-title><fpage>160</fpage><lpage>165</lpage><history><date date-type="received" iso-8601-date="2020-07-21"><day>21</day><month>07</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2018, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2018, ООО "Эко-Вектор"</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">ООО "Эко-Вектор"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2025-01-01"/></permissions><self-uri xlink:href="https://rjmseer.com/1560-9537/article/view/36003">https://rjmseer.com/1560-9537/article/view/36003</self-uri><abstract xml:lang="en"><p>Drug reimbursement is one of the key elements of the effective health care system. The introduction of mechanisms to optimize the cost of drug provision can significantly reduce the costs of the state budget, expanding the availability of therapy and reducing long-term economic losses due to disability of the working population. The article analyses the specifics of drug provision programs in various regions of the world to determine the best practices for the purpose of subsequent introduction in the Russian Federation.</p></abstract><trans-abstract xml:lang="ru"><p>Лекарственное обеспечение является одним из основных элементов формирования эффективной системы оказания медицинской помощи. Внедрение механизмов оптимизации затрат на лекарственное обеспечение позволяет существенно сократить затраты государственного бюджета, расширив доступность терапии и уменьшив долгосрочные потери экономики вследствие инвалидизации трудоспособного населения. В статье рассмотрена специфика реализации программ лекарственного обеспечения в различных регионах мира для определения наиболее эффективных подходов по оптимизации расходов на лекарственное обеспечение с целью последующего внедрения в систему организации медицинской помощи в РФ.</p></trans-abstract><kwd-group xml:lang="en"><kwd>medical insurance</kwd><kwd>drug reimbursement</kwd><kwd>USA Canada</kwd><kwd>Germany</kwd><kwd>Australia</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>медицинское страхование</kwd><kwd>лекарственное обеспечение</kwd><kwd>США</kwd><kwd>Канада</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Власов В.В., Плавинский С.Л. Варианты лекарственного обеспечения для России: уроки стран Европы и всего мира. Москва, 2012.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>CMS What’s an ACO? Centers for Medicare and Medicaid Services, 2012. (https://www.cms.gov/ACO/, accessed 19 April 2013).</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Pharmaceutical Research and Manufacturers of America (PhRMA). Medicare Part D: A Success Story, http://www.phrma.org/issues/medicare (accessed May 16), 2013.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>German Pharmaceutical Industry Association/BPI, based on 1. IMS World Review 2012.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Sieler S., Rudolph T., Brinkmann-Sass C., Sear R. How has German health reform impacted pharma pricing and market access, and what can the industry learn from the experience? Country Focus. Germany. McKinsey. 2015.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Workplace and Employee Survey Compendium. Statistics Canada. 2008. http://www.statcan.gc.ca/pub/71-585-x/71-585-x2008001-eng.pdf. Low Earnings, Unfilled</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Prescriptions: Employer-Provided Health Benefit Coverage in Canada. Wellesley Institute. 2015.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Prescription drug access and affordability an issue for nearly a quarter of all Canadian households. Angus Reid Institute. 2015 http://angusreid.org/</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>The effect of cost on adherence to prescription medications in Canada. Canadian Medical Association Journal. 2012. http://www.cmaj.ca/</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Clinical Service Proposal: Medication Adherence Services. British Columbia Pharmacy Association. 2013. http://www.bcpharmacy.ca/uploads/Medication_Adherence.pdf</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Kennedy J., Morgan S. Cost-related prescription nonadherence in the United States and Canada: A system-level comparison using the 2007 international health policy survey in seven countries. Clinical Therapeutics. 2093; 1 (1): 213-9.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Demers V., Melo M., Jackevicius C., Cox J., Kalavrouziotis D., Rinfret S., Humphries K., Johansen H., Tu J., Pilote L. Comparison of provincial prescription drug plans and the impact on patients’ annual drug expenditures. CMAJ. 2008; 178: 405-9.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Pharmacare costing in Canada Preliminary Report: Assessment of a National Pharmacare Model Cost Estimate Study PDCI Market Access Inc. Commissioned by the Canadian Pharmacists Association January 19, 2016.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Reforming private drug coverage in Canada: Inefficient drug benefit design and the barriers to change in unionized settings. Health Policy.2015. http://www.ncbi.nlm.nih.gov/pubmed/25498311</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Government of Ontario, Ministry of Health and Long-Term Care. Transparent Drug System for Patients Act, 2006. Legislation. MOHLTC. http://www.health.gov.on.ca/en/common/legislation/bill102/.McArthur D. The current paradigm of drug funding: a public funder’s perspective. In: Provincial Industry Payer Agreements in an Era of National Purchasing Strategies Roundtable Discussion, St. John’s, Canada, May 2013.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Sapsford R. Delivering world class value for money in provincial drug system. 2009.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>McArthur D. The current paradigm of drug funding: a public funder’s perspective. In: Provincial Industry Payer Agreements in an Era of National Purchasing Strategies Roundtable Discussion, St.John’s, Canada, May 2013.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Boehringer Ingelheim (Canada) Ltd. v. Canadian Agency for Drugs and Technologies In Health, 2008 55998 (ON SCDC). 510/08. Ontario Superior Court of Justice, Oct 29, 2008.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Australian Government, Department of Health and Ageing (2013a) Annual report 2012-2013. http://www.health.gov.au/internet/main/publishing.nsf/Content/annual-report 2012-13.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Australian Government, Department of Health (2019) Fees, patient contributions and safety net thresholds. History of PBS copayments and safety net thresholds. http://www.pbs.gov.au/info/healthpro/explanatory-notes/front/fee.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>The Commonwealth of Australia (2011) Framework for the introduction of parallel TGA and PBAC processes. http://www.pbs.gov.au/info/publication/factsheets/shared/framework-forintroduction-of-parallel-TGA-and-PBAC-processes.</mixed-citation></ref></ref-list></back></article>
